-
Canan Schuman, PharmD/PhD
Posts
Report Study | Impact of COVID-19 on the Global Rare Neurodegenerative Disease Treatment Market
A new study on the Rare Neurodegenerative Disease Treatment market provides a detailed overview of the demands and consumptions of various products/services associated with the...
Bay Area woman lobbying for passage of ALS bill
When Jamie Berry noticed a slight limp in her right foot in late May, she didn’t think much of it. Berry tends horses and drives...
Is Sorrento Therapeutics Stock a Buy?
Back in May, Sorrento Therapeutics (NASDAQ:SRNE) captivated investor attention after it claimed the discovery of an antibody that can provide “100% inhibition” against COVID-19. In...
REGENERON’S ANTIBODY COCKTAIL REGN-EB3 (INMAZEB®) IS FIRST FDA-APPROVED TREATMENT FOR EBOLA (ZAIRE EBOLAVIRUS)
In a large clinical trial, Inmazeb showed superiority compared to other investigational agents (ZMapp and remdesivir) with respect to mortality; treatment was most effective when...
Bausch Health And BHVI Announce Exclusive Global Licensing Agreement For Myopia Control Contact Lens
Second Exclusive License Strengthens Bausch + Lomb’s Global Research Focus on Myopia SYDNEY and LAVAL, QC, Oct. 15, 2020 /PRNewswire/ — Bausch Health Companies Inc. (NYSE/TSX: BHC)...
Japan Grants Patent to Brainstorm Covering Technique for NurOwn
The Japan Patent Office has granted a patent to Brainstorm Cell Therapeutics covering the proprietary technique that generates the company’s cell-based therapy NurOwn from mesenchymal...
Fierce Innovation Awards — Life Sciences Edition 2020: Winners Announcement!
The Fierce Innovation Awards: Life Sciences Edition have come to a close and we’re pleased to announce the 2020 award winners! These awards are designed...
Novartis presents data at ACTRIMS-ECTRIMS for Kesimpta® (ofatumumab) in newly diagnosed treatment-naïve adults with relapsing multiple sclerosis
New post hoc data from Phase III ASCLEPIOS trials showed newly diagnosed, treatment-naïve patients experienced reductions in annualized relapse rates, MRI lesion activity and reductions...
Trump Administration’s Operation Warp Speed Accelerates AstraZeneca COVID-19 Vaccine to be Available Beginning in October
Responding to President Trump’s call to develop 300 million doses of SARS-CoV-2 vaccine by January under Operation Warp Speed, the U.S. Department of Health and...
NOVARTIS IMMUNO-ONCOLOGY DRUG CANDIDATE FAILS SKIN CANCER TRIAL
ZURICH (Reuters) – Swiss drugmaker Novartis said on Saturday that its investigational spartalizumab immuno-oncology drug mixed with the approved medicines Tafinlar and Mekinist failed in...